COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
ChiCTR2000032459 Sinopharm-Beijing Xia S, Lancet Infect Dis, 2020 () Full text Commentary |
Inactivated virus |
BBIBP-CorV 8mcg Day 0 BBIBP-CorV 4mcg D0/14 BBIBP-CorV 4mcg D0/21 BBIBP-CorV 4mcg D0/28 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old in a single centre in China | N=448 |
Some concerns Details |
|